Register Financial Advisors’s Moderna MRNA Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-35	Closed	-$3.73K	–	758
2024 Q1	$3.73K	Buy	+35	New	+$3.53K	﹤0.01%	639

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Register Financial Advisors's MRNA Position: Q2 2024 in Review

Register Financial Advisors sold out of Moderna (MRNA) in Q2 2024, closing a stake of 35 shares — an estimated $3.73K sold.

Register Financial Advisors first reported a position in MRNA in Q1 2024 and held it in 1 quarter. The position peaked at $3.73K in Q1 2024. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

Register Financial Advisors reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
Register Financial Advisors sold 35 Moderna shares in Q2 2024, an estimated $3.73K.
Register Financial Advisors first reported a position in Moderna in Q1 2024 and held it in 1 quarter.
Register Financial Advisors's Moderna position peaked at $3.73K in Q1 2024.
954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Register Financial Advisors's 13F filing for Q2 2024, filed 12 Jul 2024.